For laboratory use only. This product is intended for animal research only and not for use in humans.
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
FolateRSense™ targeted fluorescence imaging agent is highly specific and sensitive in its detection of Folate Receptor alpha (FRA) and can be used to closely monitor and quantitate tumor growth and metabolism. Over-expression of FRA protein is associated with tumor growth, and uptake of folic acid is a necessary part of tumor metabolism.
|Fluorescent Agent Type||Targeted|
|Optical Imaging Classification||Fluorescence Imaging|
|Product Brand Name||FolateRSense|
|Quantity in a Package Amount||1.0 Units|
|Therapeutic Area||Inflammation, Oncology/Cancer|
|Unit Size||1 Vial (10 doses)|
|Wave Length||680 nm|
Overexpression of Folate Receptor (FR) protein is associated with tumor growth, and uptake of folic acid is a necessary part of tumor metabolism. The FolateRSense imaging agent is highly specific and sensitive in its detection of FR and can be used to closely monitor and quantitate tumor growth and metabolism.
Folic acid (vitamin B9) is an essential nutrient required by eukaryotic cells for survival that is acquired and internalized via folate receptors (FR) on the cell surface. In particular, it is the highly metabolic cells that upregulate FR, and many different human tumor cells, including ovarian, breast, cervical, renal, colorectal and nasopharyngeal cancer cells show significant upregulation as compared to normal tissues. As such, folic acid has been successfully exploited as a cancer specific targeting moiety for the efficient delivery of chemotherapeutic agents, drug carriers, photosensitizers and diagnostic reporters. Critical to the success of such agents is the determination of the level of FR expression for a given tumor, since weak FR-expressing cancers will not respond well to folate-targeted therapies. There is therefore a need for specific and quantitative imaging agents
The primary goal of preclinical imaging is to improve the odds of clinical success and reduce drug discovery and development time and costs. Advances in non-invasive in vivo imaging techniques have raised the use of animal models in drug discovery and development to a new level by enabling quick and efficient drug screening and evaluation. Read this White Paper to learn how preclinical in vivo imaging helps to ensure that smart choices are made by providing Go/No-Go decisions and de-risking drug candidates early on, significantly reducing time to the clinic and lowering costs all while maximizing biological understanding.